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Cr2, a Candidate Gene in the Murine Sle1c Lupus
Susceptibility Locus, Encodes a Dysfunctional Protein
NZM2410-derived disease susceptibility loci were gen-
erated on a C57BL/6 background (Morel et al., 1996).
Functional analysis of these mice showed that each
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locus confers a unique phenotype. B6.Sle1 mice pro-1Departments of Medicine and Immunology
duce high levels of anti-nuclear antibodies, indicating a2 Department of Biochemistry and Molecular Genetics
loss of tolerance to chromatin (Mohan et al., 1998), whileUniversity of Colorado Health Sciences Center
B6.Sle2 demonstrate B cell hyperactivity (Mohan et al.,Denver, Colorado 80262
1997) and B6.Sle3 exhibit dysregulation of the T cell3 Harold C. Simmons Arthritis Research Center
compartment (Mohan et al., 1999). Although none ofand Department of Internal Medicine
the individual congenic mice manifest full-blown lupus,4 Center for Immunology
severe disease can be reconstituted by combining Sle1University of Texas-Southwestern Medical Center
with Sle2 or Sle3, demonstrating that Sle1 is critical forDallas, Texas 75235
the development of lupus nephritis (Morel et al., 2000).5 Departments of Medicine and Pathology
In addition, we have shown the existence of negativeUniversity of Florida
modifier loci (Sles1-4) that, by specifically suppressingGainesville, Florida 32608
the Sle1 phenotypes, completely inhibit SLE pathogene-
sis (Morel et al., 1999). The Sle1 interval is located in a
region of chromosome 1 that has been linked with SLESummary
susceptibility in multiple human ethnic groups and
mouse strains (Harley et al., 1998; Wakeland et al., 1999).The major murine systemic lupus erythematosus (SLE)
Taken together, these data suggest that loss of toler-susceptibility locus, Sle1, corresponds to three loci
ance to chromatin mediated by Sle1 is essential forindependently affecting loss of tolerance to chromatin
disease pathogenesis and that the proteins encoded byin the NZM2410 mouse. The congenic interval corre-
these loci and the pathways on which they impact maysponding to Sle1c contains Cr2, which encodes com-
be important targets for disease intervention in SLE.plement receptors 1 and 2 (CR1/CR2, CD35/CD21).
Recently, we have shown that Sle1 corresponds toNZM2410/NZW Cr2 exhibits a single nucleotide poly-
at least three loci (Sle1a, Sle1b, and Sle1c) that eachmorphism that introduces a novel glycosylation site,
independently affects the loss of tolerance to chromatin,resulting in higher molecular weight proteins. This
but presents distinct immunological characteristicspolymorphism, located in the C3d binding domain, re-
(Morel et al., 2001). In contrast to B6.Sle1a and B6.Sle1b,duces ligand binding and receptor-mediated cell sig-
the B6.Sle1c congenic strain is characterized by anti-naling. Molecular modeling based on the recently
bodies to chromatin that are not restricted to the H2A/solved CR2 structure in complex with C3d reveals that
H2B/DNA subnucleosome and that are producedthis glycosylation interferes with receptor dimeriza-
equally in males and females. In addition, the level oftion. These data demonstrate a functionally significant
serum IgM in B6.Sle1c mice is lower than in B6 controls,phenotype for the NZM2410 Cr2 allele and strongly
and they accumulate a significantly higher percentagesupport its role as a lupus susceptibility gene.
of activated CD4 splenic T cells (Morel et al., 2001).
The congenic strain B6.Sle1c contains within its intervalIntroduction
the gene Cr2, which encodes complement receptors 1
and 2 (CR1/CR2, CD35/CD21) by alternative splicing of
Female (NZB  NZW)F1 mice develop a clinical picture a single mRNA transcript (Kurtz et al., 1990; Molina et
similar to human SLE, with the production of IgG anti-
al., 1990). In humans, CR1 and CR2 are generated from
dsDNA autoantibodies and the evolution of a fatal im- two distinct but closely linked genes on chromosome
mune complex-mediated glomerulonephritis. Disease 1. The murine Cr2 gene encodes both the 190 kDa CR1
susceptibility has been linked to genes derived from protein consisting of 21 repeating structures (termed
both the NZB and NZW parental strains. Various strate- short consensus repeats or SCRs), a transmembrane
gies have been used to identify the specific disease- domain, and a short cytoplasmic tail, as well as the
related genes in these animals. One approach has uti- alternatively spliced 140 kDa CR2 protein, containing
lized the lupus-prone NZM2410 strain, a recombinant the 15 membrane-proximal SCRs of CR1 plus its trans-
inbred strain derived from (NZB  NZW)F1 mice (Rudof- membrane domain and cytoplasmic tail. CR1 and CR2
sky et al., 1993). NZM2410 mice exhibit a severe lupus are surface glycoproteins that, in the mouse, are located
phenotype, including fatal glomerulonephritis. We have almost exclusively on mature B cells and follicular den-
identified by linkage analysis three recessive loci strongly dritic cells (FDC). These receptors bind C3 and C4 degra-
associated with lupus susceptibility in this strain (Sle1, dation products that have become covalently bound to
Sle2, and Sle3 located on chromosomes 1, 4, and 7, antigen or immune complexes in the process of comple-
respectively) (Morel et al., 1994). ment activation. Previous studies have demonstrated a
In order to identify specific disease-related genes, role for CR2 in humans or CR1/CR2 in mice in lowering
B6.NZM congenic mice containing the individual the threshold for B cell activation (Carter et al., 1988;
Fingeroth et al., 1989; Luxembourg and Cooper, 1994),
rescuing B cells from surface IgM (sIgM)-mediated apo-6 Correspondence: susan.boackle@uchsc.edu
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ptosis (Kozono et al., 1995), targeting immune com-
plexes to germinal centers (Klaus, 1978; Papamichai
et al., 1975), and processing and presenting antigen
(Arvieux et al., 1988; Boackle et al., 1997, 1998; Lanza-
vecchia et al., 1988; Thornton et al., 1994). Mice rendered
deficient in CR1/CR2 by homologous recombination
(Cr2/) have defects in primary and secondary IgG re-
sponses to T-dependent antigens, germinal center for-
mation, and the generation of memory B cells (Ahearn
et al., 1996; Croix et al., 1996; Molina et al., 1996; Wu
et al., 2000).
CR1 and CR2 have been proposed to play a role in
the development of SLE. Patients with SLE have 50%
Figure 1. Genetic Map of the B6.Sle1c Congenic Strainlower levels of these receptors on their B cells (Levy et
The upper part of the figure represents the telomeric end of chromo-al., 1992; Marquart et al., 1995; Wilson et al., 1986).
some 1, with D1MIT markers shown. The map location of these
MRL/lpr mice, which develop severe lupus-like disease, markers has been calculated on a panel of 493 (B6  NZM2410)
exhibit lower levels of these receptors on B cells prior meioses, with D1MIT37 located 101 cM from the centromere as
to the onset of clinical disease, suggesting that the re- the anchor locus. Under the chromosome 1 line are shown the
approximate positions of relevant genes in relation to these markers.duction in CR1/CR2 expression may be pathogenic (Ta-
The position of the NZM2410-derived congenic interval for B6.Sle1ckahashi et al., 1997). Furthermore, when the inactivated
is shown as a hatched box, with the thin line between D1MIT407Cr2 allele was introduced in a homozygous state into
and D1MIT274 indicating the area of recombination between the
the B6/lpr background, the autoimmune disease that NZM2410 and B6 genomes.
developed, which is usually mild and occurs late, was
more severe and had a much earlier onset (Prodeus et
al., 1998). These data suggest that alterations in expres- (Molina et al., 1994). After SDS-PAGE and immunoblot-
sion or function of CR1/CR2 may affect negative selec- ting with HRP-streptavidin, CR1 and CR2 from B6.Sle1c
tion of autoreactive B cells, resulting in the initiation or were found to migrate at a higher molecular weight than
exacerbation of SLE. the corresponding proteins from B6 animals (Figure 2A).
Because of the previous association of CR1/CR2 defi- This difference was due to differential glycosylation of
ciency with autoimmune disease and the location of the the proteins, as treatment with PNGaseF reduced the
Cr2 gene within the Sle1c disease susceptibility locus, proteins from the two strains to equivalent molecular
we analyzed the Sle1c (NZW) allele of Cr2 in B6.Sle1c weights (Figure 2B). To ensure that this difference did
mice for alterations in structure, function, and expres- not reflect a global alteration in glycosylation of B cell
sion. We identified a structural difference in a critical surface receptors in the B6.Sle1c strain, CD19 and CD22
ligand binding domain of Sle1c CR1/CR2, which results were analyzed in a similar fashion and were found to be
in significant impairment in receptor function. These re- similar in size in B6 and B6.Sle1c, whether glycosylated
sults demonstrate a functionally significant effect of the or deglycosylated (Figure 2B). These data demonstrate
NZM2410 Cr2 allele and strongly support its role as a that the enhanced glycosylation of CR1 and CR2 in
disease susceptibility gene in this interval. B6.Sle1c is an alteration unique to these two proteins.
A Single-Nucleotide Polymorphism (SNP) in NZW Cr2Results
Introduces a Novel N-Linked Glycosylation Site
in the Ligand Binding Domain of CR1/CR2The NZW Allele of Cr2, Located within the Sle1c
Disease Susceptibility Interval, Generates Having identified an alteration in the structure of CR1/
CR2, the sequence of Cr2 in B6.Sle1c mice was thenProtein Products that Are Structurally
Different from Their B6 Counterparts determined in order to identify nucleotide polymor-
phisms that might confer new N-linked glycosylationThe subcongenic strain B6.Sle1c was derived from the
parental B6.Sle1 strain by generation of mice with re- sites. At nucleotide 1342, a base change of C to A was
identified, resulting in an amino acid change of histidinecombinant intervals that maintained a positive pheno-
type for loss of tolerance to chromatin (Morel et al., to asparagine. This introduced a new N-linked glycosyl-
ation site into SCR1 of CR2 (Figure 2C), which corre-2001). B6.Sle1c mice specifically contain the congenic
NZM2410 interval that spans the microsatellite marker sponds to SCR7 of CR1. It also resulted in a new BsmI
restriction endonuclease site, allowing genomic DNAD1Mit274 to the telomeric end of chromosome 1. We
have previously shown that this NZM2410 region was from a panel of autoimmune and nonautoimmune mouse
strains to be tested for the presence of this polymor-derived from NZW (Morel et al., 1996). The Sle1c interval
is approximately 3 cM in length, and contains several phism. In addition to NZW, only two other strains in this
group share this polymorphism: NOD, which developspotential SLE susceptibility genes, including Cr2, Crry,
and Cd34 (Figure 1). autoimmune diabetes (Leiter, 1993), and SWR, which
when crossed with NZB results in female progeny thatTo determine whether the Cr2 gene products were
altered in B6.Sle1c mice, CR1 and CR2 were immuno- develop a severe lupus-like disease (Eastcott et al.,
1983). Both of these strains share common ancestryprecipitated from surface-biotinylated splenic cell sus-
pensions with a mAb to CR1/CR2, 7E9, which binds to through their derivation from “Swiss” mice (Leiter, 1998).
Four other autoimmune strains (BXSB, MRL, NZB, andan epitope within the SCRs common to both receptors
Cr2 as a Lupus Susceptibility Gene
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Figure 2. Increase in Molecular Weight of CR1/CR2 in B6.Sle1c B
Lymphocytes due to Differential Glycosylation of the Proteins
(A) Splenic cell suspensions were depleted of RBC and surface
biotinylated. CR1/CR2 were immunoprecipitated with mAb 7E9,
which binds an epitope shared by the two receptors. Immunoprecip-
itates were analyzed by SDS-PAGE, transferred to a nitrocellulose
filter, and detected by HRP-streptavidin.
(B) Immunoprecipitates of CR1/CR2, CD19 and CD22 from surface
biotinylated splenic cells were either untreated () or treated ()
with PNGaseF prior to SDS-PAGE and HRP-streptavidin Western
blotting.
(C) Nucleotide and amino acid sequences demonstrating the single-
nucleotide polymorphism and amino acid change in SCR1 of CR2
(SCR7 of CR1) that introduces a novel N-linked glycosylation site.
Sequences shown were generated by RT-PCR of splenic mRNA.
The polymorphic nucleotide was confirmed by restriction digestion
of independent RT-PCR products using BsmI.
SJL) as well as five nonautoimmune strains (BALB/c,
DBA/2, AKR, C3H, and FVB) were all negative by RFLP
for this 1342 C→A polymorphism (Table 1). Interestingly,
CR1/CR2 in SWR and NOD also migrate at higher appar-
ent molecular weights than the B6 proteins in SDS-
PAGE, with initial analyses of the glycosylation status
of these proteins strongly suggesting that the molecular
weights of the core proteins are equivalent (data not
shown). No other glycosylation sites introduced by
unique polymorphisms in the N2W, SWR and NOD Cr2
genes were identified. These data suggest that the novel
glycosylation site introduced by the polymorphism in
SCR1 of CR2 is utilized in each strain in which it is
present.
A total of 16 nucleotide sequence differences were
identified in the NZW Cr2 allele as compared with B6.
This represents a mutation rate that is 3-fold higher
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than expected, based on genotyping of SNPs between
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Figure 3. Impaired Ability of B6.Sle1c CR1/
CR2 to Bind rC3dg Tetramers
(A) rC3dg tetramers prepared from 2 g of
biotin-rC3dg and 0.4 g of PE-streptavidin
were incubated with RBC-depleted splenic
cells for 30 min at 4C. FITC B220-positive
B6.Sle1c cells (dashed line) and B6 cells (thin
solid line) were analyzed for binding of im-
mune complexes by flow cytometry. Binding
of PE-SA prepared without the addition of
rC3dg to B220 B6 cells is demonstrated by
the thick line. Identical control binding to
B220 B6.Sle1c cells was seen (data not
shown). These data are representative of
three separate experiments.
(B) A stock mixture of 2 g b-rC3dg and 0.4
g of PE-streptavidin was prepared. B6 and
B6.Sle1c B cells were incubated with dilu-
tions of rC3dg tetramers then analyzed by
flow cytometry. In each of three separate ex-
periments, the sample with the maximal mean
fluorescence intensity was set at a relative
value of 100 and the other samples normal-
ized to this value. The average and SEM of the normalized values for mean fluorescent intensity (MFI) are demonstrated.
(C and D) RBC-depleted splenic cells were stained with anti-CR1 (8C12; C) and anti-CR1/CR2 (4E3; D) and B220-positive B6.Sle1c cells
(dashed line) and control B6 cells (thin line) were analyzed for expression of these receptors by flow cytometry. Binding of an isotype control
antibody (thick line) is also indicated. These data are representative of three separate experiments.
lab strains (Lindblad-Toh et al., 2000). These sequence human C3d for mouse CR2 is indistinguishable from
that for human CR2 (Molina et al., 1991). In addition, adifferences included 11 SNPs that resulted in amino
acid changes and one 3 base insertion, resulting in the human CR2 transgene can reconstitute the immunologi-
cal defects identified in Cr2/ mice (Marchbank et al.,addition of a lysine residue in SCR5 of the CR1 protein
(Table 1). In addition, four SNPs resulted in no amino 2000). Based on these data, we believe that human
rC3dg is an acceptable reagent for the study of endoge-acid changes (A→G at nucleotide 243, T→C at nucleo-
tide 933, T→G at nucleotide 2367, and C→ T at nucleo- nous CR2 function in mice.
Most of the B6.Sle1c B cells bound tetramers at levelstide 2736). Two other single nucleotide changes (C →
G at nucleotide 908, G → C at nucleotide 909) and one more than an order of magnitude lower than B6 (Figure
3A). The mean fluorescence intensity (MFI) of tetramer6 base deletion of nucleotides 4038–4043, although dif-
ferent from the published sequence for Cr2 (Fingeroth, binding to B6.Sle1c B cells was 25%–33% lower than
to B6, with this difference being maintained over each1990; Kurtz et al., 1990; Molina et al., 1990), were identi-
fied in both B6 and B6.Sle1c. dilution of the tetramers (Figure 3B). To ensure that this
decrease in ligand binding was not due to altered ex-In addition to the polymorphism in SCR7/SCR1 noted
above, six additional alterations were tested in other pression of CR1/CR2 on B6.Sle1c B cells, analysis of
CR1/CR2 mAb binding to B220 splenic cells was per-strains using RFLP-PCR or direct sequencing (Table 1).
The polymorphisms in SCR13/SCR7 and SCR16/SCR10 formed. 8C12 is specific for an epitope within SCR3 and
SCR4 of CR1 (Molina et al., 1994), while 4E3 binds bothhad the same strain distribution pattern as the SCR7/
SCR1 polymorphism, while the SCR5 polymorphism receptors at a shared epitope within SCR1 and SCR2
of CR2 (SCR7 and SCR8 of CR1). The expression of CR1was shared with SJL, and the SCR9/SCR3 polymor-
phism was shared with MRL, NZB, BALB/c, and DBA/2. and CR2 on the cell surface was equivalent in B6 and
B6.Sle1c (Figures 3C and 3D). These results are alsoThe SNPs in the transmembrane and cytoplasmic do-
mains were unique to NZW. consistent with the similar levels of protein that are im-
munoprecipitated from each strain (Figure 2A and 2B).
These results strongly suggest that decreased bindingBinding of C3dg Ligand to B6.Sle1c B Cells
Is Decreased of ligand by the NZW Cr2 allele is a result of the structural
alteration identified in SCR7/SCR1 of CR1/CR2.SCR1 and SCR2 of CR2 (SCR7 and SCR8 of CR1) serve
as the primary ligand binding site for C3d- and C3dg- Binding of rC3dg tetramers to CR1 and CR2 is depen-
dent upon the level of expression of the receptors, baseddegradation products of complement covalently bound
to antigen (Molina et al., 1994; Pramoonjago et al., 1993). on studies in K562 cells transfected with mouse CR1 and
CR2 (data not shown). The overall binding of tetramers toWe reasoned that the introduction of a new N-linked
glycosylation site in SCR1 of CR2 in B6.Sle1c could B cells from each strain is heterogeneous, likely due to
tetramer binding to splenic B cell subpopulations thatinterfere with ligand binding. To test this hypothesis,
recombinant C3dg tetramers (rC3dg tetramers), pre- express variable levels of CR2. CR1/CR2 expression
varies among mouse splenic subpopulations by approx-pared with biotinylated recombinant human C3dg
(b-rC3dg) and PE-streptavidin, were bound to B6 and imately 10-fold (Takahashi et al., 1997). We confirmed
that the major B cell subpopulations (follicular and mar-B6.Sle1c splenic cell preparations and analyzed by flow
cytometry. Previous studies have shown that the Kd of ginal zone) in B6 and B6.Sle1c mice are present in identi-
Cr2 as a Lupus Susceptibility Gene
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cal proportions (data not shown). Therefore, the varia- at 21 days in B6.Sle1c compared with B6 mice (p 0.07
for IgM and p 0.10 for IgG by Student’s t test) (Figurestion in rC3dg tetramer binding identified within each
4G and 4H). At 28 days, levels of IgG anti-DNP werestrain is likely due to differences in receptor level on
significantly decreased by20% in B6.Sle1c comparedvarious subpopulations of B cells, while the differences
with B6 mice (p  0.009) (Figure 4H). Interestingly, thisin tetramer binding between the two strains are due to
difference was primarily due to differences in IgG3 anti-differences in receptor affinity or avidity.
DNP levels (O.D. at 1:100 dilution of 997  290 for B6
versus 230  15 for B6.Sle1c; p  0.01), which is theCR1/CR2-Mediated Signaling Is Diminished
isotype predominantly affected in secondary responsesin B6.Sle1c B Cells
to T-dependent antigens in Cr2/ mice (Molina et al.,As one means to determine whether the polymorphisms
1996). These data provide additional support for an inin B6.Sle1c Cr2 confer a functional effect, signaling
vivo functional alteration of CR1/CR2 in B6.Sle1c mice.through CR1/CR2 was studied. Cocrosslinking CR2 and
sIgM has been shown to lower the threshold by which
Analysis of the Ligand Binding Domain of B6.Sle1cB cells can be activated through sIgM (Carter et al.,
Cr2 by Molecular Modeling Based on the Human1988). We have previously demonstrated that calcium
CR2 Crystal Structureflux can be induced in resting murine B cells by cocross-
Recently, the 3-D structure of the complex containinglinking CR1/CR2 and sIgM with streptavidin-linked com-
the SCR1 and SCR2 ligand binding domain of humanplexes of b-rC3dg and biotinylated anti-sIgM (b-7-6). At
CR2 in association with C3d has been determined (Sza-the subthreshold doses of b-rC3dg and biotinylated
konyi et al., 2001). In the crystal structure, we found thatanti-sIgM used, a response could only be seen if both
CR2 forms dimers via SCR1-SCR1 interactions (Szako-reagents were combined in the tetramers (Henson et
nyi et al., 2001) (Figure 5A). The dimer structure showsal., 2001). Calcium flux induced by these complexes
a moderate set of hydrogen bonds formed between resi-requires CR1/CR2, as it did not occur when stimulating
dues of the E1  strand of one molecule and the D2 Cr2/ B cells. Crosslinking the receptors is also re-
strand of another molecule, establishing a symmetricalquired, as no response was seen when the cells were
contact with the E1 strands from each molecule runningincubated with b-rC3dg and biotinylated anti-sIgM in
antiparallel to the other (Figure 5B). Of interest, molecu-the absence of streptavidin.
lar modeling of the mouse CR2 sequence reveals thatWhen B6.Sle1c B cells were stimulated with tetramers
the altered residue (asparagine) in the polymorphicprepared using subthreshold doses of b-C3dg and bio-
SCR1 of B6.Sle1c CR2 is located at the equivalent posi-tinylated anti-sIgM, several differences in calcium re-
tion of human D53, a site that is critical for the dimeriza-sponses were identified in comparison with the re-
tion of CR2 (Figure 5B). Regardless of the rotamer con-sponses from B6 B cells. The mean number of cells
formation of the asparagine side chain at this position,responding was decreased by 20%–40% (Figures 4A
the N-linked polysaccharide to this asparagine residueand 4C), and the mean amplitude of the response was
(Figure 5C) would alter dimerization, either by direct ordecreased by 25%–50% (Figures 4B and 4D). Further-
indirect interference with hydrogen bond formation.more, the time to peak response was increased. When
An alternative possibility we have considered iseither a strong [F(ab)	2 goat anti-mouse Ig; Figures 4E whether glycosylation at this site would directly interfereand 4F] or intermediate (tetramers containing higher
with C3d binding by CR2. However, C3d ligand binding
doses of biotinylated anti-sIgM; data not shown) anti-
to CR2 occurs via interactions of ligand with the SCR2
sIgM stimulus was used to crosslink the B cell receptor
domain of CR2 (Szakonyi et al., 2001). Because of the
(BCR) alone, B cells from both strains responded simi- side-to-side packed structure of SCR1-SCR2 demon-
larly in the numbers of cells responding and the ampli- strated in the cocrystallized molecules (Szakonyi et al.,
tude of the response. These results demonstrate that B 2001), the distance between position D53 in SCR1 and
cells from the two strains generate equivalent signals the C3d binding interface of SCR2 would, in principle,
through the BCR but that the altered B6.Sle1c CR2 allele allow a cis inhibition effect on ligand binding by a poly-
is unable to function optimally to lower the threshold saccharide at the D53 position that has a linear chain
for B cell activation through sIgM. length of 10 sugar residues. However, molecular model-
ing reveals that it would be very unlikely due to steric
Humoral Immune Response to T-Dependent Antigens hindrance for a normally branched N-linked polysaccha-
Is Diminished in B6.Sle1c Mice ride to reach from D53 to the ligand binding interface
To further test the function of B6.Sle1c CR1/CR2, we on SCR2. It is also unlikely that a change in secondary
analyzed B6.Sle1c mice for the presence of alterations structure of the SCR1 domain due to this polymorphism
in immune responses that have been identified in Cr2/ would have an impact on the ligand binding domain
mice. Several independent studies have shown that in SCR2. Therefore, it is most likely that the primary
Cr2/and Cr2/mice have an impaired ability to mount functional effects of the SCR1 polymorphism identified
normal humoral responses to T-dependent foreign anti- in B6.Sle1c B cells are mediated by interference with
gens (Ahearn et al., 1996; Croix et al., 1996; Molina et the dimerization interface rather than by direct inhibition
al., 1996). B6 and B6.Sle1c mice were immunized intra- of ligand binding.
peritoneally with the T-dependent antigen DNP-KLH in
alum on days 0 and 21. Sera obtained on days 21 and Discussion
28 were tested by ELISA for the presence of IgM and
IgG anti-DNP antibodies. There was a trend toward a We describe here the identification of an altered Cr2
allele in the Sle1c disease susceptibility interval of thesignificant decrease in both IgM and IgG anti-DNP levels
Immunity
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Figure 4. Impaired Functional Responses in
B6.Sle1c CR1/CR2
(Panels A–F) Indo1-AM-loaded B cells were
stimulated with tetramers prepared with vary-
ing amounts of b-rC3dg plus 0.125 ug of bio-
tinylated anti-sIgM (b-7-6) and 0.2 g strep-
tavidin in order to cocrosslink CR2 and sIgM.
B220-positive cells were analyzed for in-
creases in the intracellular concentration of
calcium. Panels (A) and (B) and panels (C)
and (D) represent separate experiments, each
using cells purified from a single B6 and a
single B6.Sle1c mouse. The percent of cells
with intracellular calcium at levels 
10%
above baseline (A and C) and the mean ratio
of bound to unbound Indo1-AM (B and D)
were determined. Use of b-rC3dg or biotinyl-
ated b-7-6 alone at these doses resulted in
no effect on intracellular calcium levels (data
not shown). Cells were also activated with a
strongly crosslinking anti-sIg antibody (F(ab)	2
goat anti-mouse Ig; GAM) with percent cells
responding depicted in (E) and mean re-
sponse in (F). These data are representa-
tive of five separate experiments. (Panels
G–H) Five 6-week-old B6 and B6.Sle1c mice
were immunized intraperitoneally with the
T-dependent antigen DNP-KLH in alum on
day 0 and on day 21 (arrows). Sera obtained
on days 21 and 28 were tested by ELISA for
the presence of IgM (G) and IgG (H) anti-DNP
antibodies. The mean and SEM of OD read-
ings for 1:100 dilutions of sera are demon-
strated.
NZM2410 mouse model for SLE. This allele exhibits mul- and sIgM. Decreased numbers of B6.Sle1c B cells re-
sponded to coligation of CR1/CR2 and sIgM, and thetiple polymorphisms when compared to the B6 allele,
including a single-nucleotide polymorphism in the ligand amplitude of the response was lower than that in B6 B
cells. Furthermore, B6.Sle1c B cells required more timebinding domain of CR2 that introduces a new N-linked
glycosylation site. This site is utilized for glycosylation, to reach their peak response. The decreased ability of
B6.Sle1c B cells to bind ligand may explain why lessas evidenced by the increased molecular weight of CR1
and CR2 encoded by the Sle1c allele. Importantly, the cells responded, since fewer cells may bind ligand at a
level sufficient to activate the cells. The decreased li-presence of a carbohydrate group at this site would
interfere with the dimerization of CR2, as predicted by gand binding capacity of B6.Sle1c CR1/CR2 might also
diminish their ability to enhance BCR signaling withthe recently solved crystal structure of SCR1 and SCR2
of human CR2 in complex with the C3d ligand (Szakonyi comparable kinetics and amplitude to B6.
Third, B6.Sle1c mice were unable to mount normalet al., 2001).
There are several lines of evidence that support our humoral immune responses to a T-dependent foreign
antigen. Immunization with DNP-KLH resulted in aconclusion that Cr2 is the disease susceptibility gene
corresponding to the Sle1c locus. First, B6.Sle1c B cells blunted IgG anti-DNP response, similar to, although not
as marked as, that seen in Cr2/ mice (Ahearn et al.,bound rC3dg tetramers at levels much lower than B6 B
cells. Since the expression of CR1/CR2 is equivalent on 1996; Croix et al., 1996; Molina et al., 1996; Wu et al.,
2000). This was not unexpected, as the Sle1c SCR1B cells of both strains by flow cytometry and immuno-
precipitation of surface-labeled proteins, the decrease polymorphism resulted in a relative decrease in CR1/
CR2 function rather than an absolute lack of function,in binding is likely due to a decrease in receptor avidity
for ligand. more similar in nature to Cr2/ mice which demonstrate
an intermediate defect in antibody production (MolinaSecond, B cells expressing the NZW Cr2 allele were
functionally impaired, in that B6.Sle1c B cells were less and Holers, 1996; unpublished data).
We have considered how interruption of the CR2 di-able to respond to synergistic signals through CR1/CR2
Cr2 as a Lupus Susceptibility Gene
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Figure 5. SCR1 Polymorphism in B6.Sle1c
CR2 Interferes with a CR2-CR2 Dimer In-
terface
(A) The overview of the two SCR1 coming
together in a CR2 dimer (Szakonyi et al.,
2001). Each SCR1 contains four anti-parallel
 strands. Strand D2 and E1 of one CR2 mole-
cule (red) pack against strand E1 and D2 of
the second CR2 molecule in the dimer (blue).
(Prepared using RIBBONS).
(B) Detail of interactions at the SCR1 dimer-
ization interface. The CR2 dimer is formed
through hydrogen bonds (dashed line in pur-
ple) between side chain and main chain
atoms of the SCR1 domain. Some of the hy-
drogen bonds are formed via water molecules
(balls in pink). Residue D53 (corresponding
to H52 in mouse CR2) is one of the key resi-
dues in the formation of the hydrogen net-
work bonding the two CR2 molecules to-
gether. In the SCR1 polymorphism of B6.Sle1c
CR2, the D53 position is occupied by an as-
paragine residue that is glycosylated.
(C) Structure of carbohydrate chain, showing
only the first two N-acetyl-glucosamine resi-
dues in the N-linked polysaccharide. C1 of
the first residue is indicated. Residues are
drawn to scale with respect to the SCR1-
SCR1 dimerization interface shown in (B). Re-
gardless of the orientation of the glycosylated
amino group on the asparagine side chain
(due to different rotamer conformations), the
presence of even a short carbohydrate chain
would interfere with hydrogen bond forma-
tion and CR2 dimerization.
merization interface by glycosylation on SCR1 might Furthermore, interference with the dimerization inter-
face may also result in decreased signals through theaffect C3d binding, which is mediated through SCR2.
Monomeric C3d interacts with CR2 with a very low affin- BCR, independent of direct effects on ligand binding.
Previous studies of C3d acting as a molecular adjuvantity, whereas polymeric C3d has an affinity that is at least
1000-fold higher (Carel et al., 1990; Moore et al., 1989). have shown that two or three C3d molecules attached to
hen egg lysozyme (HEL) can enhance the IgG1 humoralIn addition, binding of ligand to CR2 appears to have a
threshold effect in that significant binding does not oc- response to HEL by 1000 to 10,000 times (Dempsey et
al., 1996). Based on the CR2 crystal structure, we predictcur unless cells express a certain number of receptors,
after which binding of ligand is proportional to the level that binding of C3d-bound antigen to a single BCR can
bring together through CR2 dimers twice as many CR2/of CR2 expression (Boackle et al., 1997). These data
support an important role for receptor aggregation either CD19/CD81 signaling complexes as a CR2 monomer
(Figure 6B), providing a greater enhancement of the im-promoted by or enhancing ligand binding and suggest
that a structural alteration that interferes with CR2-CR2 mune response.
CR2 dimer interactions have not been detected pre-interactions would result in decreased ligand binding.
A plausible explanation for these results based on the viously in solution studies using gel filtration or ultracen-
trifugation (Moore et al., 1989), possibly due to weakCR2 crystal structure is that CR2 dimers can be brought
together by C3d ligand. CR2 dimerization would in- interactions, although strong interactions would not be
necessary on cell membranes where receptors arecrease the local concentration of receptors available
for polymeric C3d interactions, thereby increasing the largely constrained to lateral movement. Our data sug-
gest that CR2 dimerization plays a physiological role inoverall avidity of CR2-C3d interactions (Figure 6A). If
dimerization is key to promoting high-avidity receptor- ligand binding since a polymorphism that would inter-
fere with dimerization results in decreased C3d ligandligand interactions, interference with dimer formation
would decrease polymeric C3d binding as was seen in binding.
It is interesting that NOD and SWR mice share theour experiments.
Immunity
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Figure 6. Model of CR2-CR2 Dimer Forma-
tion as a Key Component of the CR2 Ligand
Binding and Signal Transduction Complex
that Is Altered in B6.Sle1c Mice
(A) Model of CR2 interacting with C3d-bound
antigen. The dimer contact is through SCR1
only, as seen in the crystal structure, while
C3d contacts SCR2. C3d interactions to CR2-
expressing cells in B6 mice are of a higher
avidity due to receptor dimerization.
(B) Model of enhanced BCR-mediated signal-
ing induced by C3d-bound antigen crosslink-
ing CR2 dimers and the BCR on the cell sur-
face. The dimer form of CR2, as opposed to
the monomer, in complex with CD19/CD81
permits C3d-bound antigen to crosslink addi-
tional CR2/CD19/CD81 signaling complexes
on the cell surface, augmenting the signal
transduced by the BCR.
SCR1 polymorphism with NZW, along with the polymor- Previous studies have suggested that Cr2 deficiency
alone on a B6 background does not confer severe auto-phisms in SCR7 and SCR10 of CR2 (SCR13 and SCR16
of CR1). These three polymorphisms may mark an allele immune disease, but may contribute to specific pheno-
types (Chen et al., 2000). Indeed, our studies suggestfor Cr2 that confers an autoimmune phenotype when
present on the appropriate genetic background. At this that the expression of the NZW CR1/CR2 allele confers
only a modest phenotype (autoreactivity to chromatin).time, however, we cannot rule out a role for the other
SCR polymorphisms in the effects on ligand binding, However, we propose that the combination of the NZW
CR1/CR2 allele with altered alleles from other diseasealthough we believe it most likely that the CR2 SCR1
polymorphism is responsible for these effects. It is likely susceptibility loci can result in a fully penetrant end-
stage disease phenotype. We and others have shownthat this polymorphism also explains the decrease in
CR2 signaling identified in B6.Sle1c B cells, although the that autoimmune diseases result from synergistic inter-
actions between susceptibility alleles that each providepolymorphisms in the transmembrane and cytoplasmic
domains of B6.Sle1c CR1/CR2 may contribute to this a small contribution to the disease phenotype (Cornall
et al., 1998; Morel et al., 2000).effect. The transmembrane domain of CR2 is critical for
the interaction of CR2 with CD19 (Matsumoto et al., There are several potential mechanisms by which dys-
function of CR1/CR2 might promote the development1993), and the polymorphism in the transmembrane do-
main of the B6.Sle1c Cr2 allele may interfere with this of autoimmunity. CR1/CR2 may play a role in the devel-
opment of central tolerance by lowering the thresholdinteraction. However, preliminary experiments have
shown that CD19 does coimmunoprecipitate with CR1/ for negative selection of autoreactive B cells, as sug-
gested by previous studies using the HEL model (Pro-CR2 in digitonin lysates of B6.Sle1c B cells (data not
shown), suggesting that this signaling complex is at deus et al., 1998). When the expression or function of
B cell CR1/CR2 is altered, autoreactive B cells may beleast physically intact. The change from a serine to an
arginine in the B6.Sle1c cytoplasmic domain may also able to escape the mechanisms that would normally
render them tolerant to autoantigen. These receptorsimpact signaling through CR2, although the functional
role of the CR2 cytoplasmic domain has not yet been may also be important in the maintenance of peripheral
tolerance by continually exposing circulating B cells toclearly determined. Our previous studies did show that
CR2 lacking the cytoplasmic domain could not be inter- autoantigen sequestered in secondary lymphoid organs
via interactions with CR1/CR2 on FDC. Finally, CR1/CR2nalized (Carel et al., 1990), providing some evidence for
a function of this domain. may play a role in generating autoimmune responses
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heim, Indianapolis, Indiana), 10 g/ml pepstatin, and phosphataseby their effects on antigen presentation. Binding and
inhibitors (0.05 mM sodium orthovanadate, 50 mM sodium fluoride,internalization of autoantigen by CR1/CR2 may result in
and 20 mM -glycerophosphate). Lysates were incubated with ratthe presentation of unique peptides that are recognized
anti-mouse CR1/CR2 (7E9), rabbit anti-mouse CD19 (rabbit anti-
by autoreactive T cells (Boackle et al., 1997, 1998). The serum, produced by S.A.B.), or rat anti-mouse CD22 (Southern Bio-
levels or types of costimulatory molecules upregulated technology Associates, Birmingham, Alabama) for 30 min on ice,
followed by addition of Protein G Sepharose (Amersham Pharmacia,may also vary when CR1/CR2 are coligated with sIg
Piscataway, New Jersey) and incubation for 1 hr at 4C. Nonreduced(Kozono et al., 1998), resulting in the skewing of T cell
samples were analyzed by 8% SDS-PAGE, transferred to a nitrocel-cytokine production to create an environment that ef-
lulose filter, and incubated with HRP-streptavidin (Zymed, San Fran-fects loss of tolerance to autoantigen.
cisco, California). In some experiments, immunoprecipitated pro-
Although the NZW Cr2 allele generates proteins that teins were deglycosylated with 0.6 U PNGaseF (New England
are structurally and functionally altered, its role in the Biolabs, Beverly, Massachusetts) for 2 hr at 37C under nondenatur-
ing conditions prior to SDS-PAGE analysis.pathogenesis of autoimmune disease will not be proven
until the Sle1c phenotypes are demonstrated to resolve
Sequencing of Cr2in the presence of normal gene products. This will re-
RNA was extracted from spleens of each of the following strains:quire the generation of transgenic B6.Sle1c mice that
B6.Sle1c, B6, NZW, NZB, BALB/c, SWR, NOD, and MRL using Trizol
overexpress B6 Cr2 gene products, studies that are in reagent (Life Sciences Technologies, Grand Island, New York). cDNA
progress. It is possible that incomplete resolution of the was generated by reverse transcription using random hexamers
autoimmune phenotype will result from these studies, (Applied Biosystems, Foster City, California), and PCR products
generated from cDNA using the following primer sets:suggesting that other disease-related genes located
within the Sle1c interval are contributing to the pheno-
Cr2-1 - 5	-CTCTTCCTCTCCTTGCTACAGGC-3	
type. We are currently generating recombinant strains Cr2-2 - 5	-GGAGATGGCTGAGGTGACTC-3	
to narrow the interval containing Cr2 so that we can Cr2-3 - 5	-CATTGGTGACTCGTCTGCTACATG-3	
Cr2-4 - 5	-GAGGTGGTAGACATCCCATGAAGC-3	further address this possibility. If our present results are
Cr2-5 - 5	-CCATGAAAGGCAGCAGAATAGCATG-3	confirmed, Cr2 will be the first SLE susceptibility gene
Cr2-6 - 5	-GACTTCAGGAGGAGGGTCACAAG-3	to be identified by linkage analysis. Additional studies
Cr2-7 - 5	-GCAAACCTTCTAGTCAGTCTATCCCAG-3	are planned to determine whether a functionally signifi-
Cr2-8 - 5	-GTCACAGACAACCCAGCAACAAAC-3	
cant polymorphism in CR2 exists in patients with SLE, Cr2-9 - 5	-CCCTCTGAGTGCCCATCAC-3	
which would strongly suggest that this gene plays an Cr2-10 - 5	-GTGAAGCTCACGCCTTTCTCTG-3	
Cr2-11 - 5	-CTACACCTGTGACCCAAGCCC-3	important role in the pathogenesis of autoimmune dis-
Cr2-12 - 5	-CCTACTGGCTTACACTCTGCAACTG-3	ease. Previous studies have already shown that CR2
Cr2-13 - 5	-GCTGTGACCCTGGCTATTTACTGG-3	levels are decreased in patients with SLE (Levy et al.,
Cr2-14 - 5	-CGGATCTGACTGCTTCCACTC-3	1992; Marquart et al., 1995; Wilson et al., 1986), support-
Cr2-15 - 5	-GTCCAGTGCACAGACGTTCATG-3	
ing either a genetic or acquired mechanism by which Cr2-16 - 5	-GTCCACTCCAAGAGCCATGACC-3	
alterations in CR2 would influence autoimmunity. Cr2-17 - 5	-GGTCATGGCTCTTGGAGTGGAC-3	
Cr2-18 - 5	-GATAAGACGTGCCTCTCCAGCC-3	Understanding the functional effects of this altered
Cr2-19 - 5	-GGCTGGAGAGGCACGTCTTATC-3	allele will allow us to better understand its impact on the
Cr2-20 - 5	-GGTGGCATGTAAGCAGATATGGTG-3	development and persistence of autoimmune disease.
Furthermore, irrespective of its role in autoimmunity, PCR, performed in a GeneAmp PCR System 9700 (Applied Biosys-
studies of this highly polymorphic allele, which gener- tems), generally utilized touchdown PCR cycling parameters (94C
2 min, 25 cycles of 94C  30 s, 65C → 55C  30 s, 72C 1 min,ates structurally and functionally altered proteins, will
followed by 15 cycles of 94C  30 s, 55C  30 s, 72C  1 min,assist in our understanding of the biology and structure-
then 72C  10 min). PCR products were purified with the QIAquickfunction relations of CR1/CR2. Both in vivo and in vitro
PCR Product Purification Kit (QIAgen, Santa Clarita, California) and
experiments, utilizing knockin strategies of various NZW sequenced with the above primers by the University of Colorado
Cr2 gene products and expression of various recombi- Cancer Center DNA Sequencing and Analysis Core Facility using
nant NZW CR1/CR2 proteins, will be utilized to clarify ABI Prism kits (Applied Biosystems) containing AmpliTaq DNA Poly-
merase FS in dRhodamine Terminator Cycle Sequencing Readythe function of these receptors and their domains in
Reaction kit (part number 404043). The reaction products were ana-normal and autoimmune responses.
lyzed on either an ABI 373A or an ABI Prism 377 DNA fluorescent
sequencer (both standard or XL versions) (Applied Biosystems).
Experimental Procedures Polymorphisms resulting in the loss or gain of restriction site were
screened on a panel of eleven mouse strains by RFLP-PCR with
Mice DNAs purchased from the Jackson Laboratory.
The production of the B6.Sle1c subcongenic strain from B6.Sle1
has been previously described (Morel et al., 2001). Mice were bred Flow Cytometry
and maintained under identical conditions at the University of Colo- Splenic cell suspensions were depleted of RBC with Gey’s solution
rado Health Sciences Center Center for Laboratory Animal Care or and FcRII receptors blocked with 2.4G2 (American Type Tissue
the University of Florida Department of Animal Resources. C57BL/6 Collection, Rockville, Maryland). B cells were incubated with saturat-
(B6) mice were obtained from the National Cancer Institute ing amounts of biotinylated rat anti-mouse CR1 (8C12) or rat anti-
(Bethesda, Maryland) and the Jackson Laboratory (Bar Harbor, mouse CR1/CR2 (4E3), followed by PE-streptavidin (Southern Bio-
Maine). technology Associates) and FITC-B220 (Pharmingen, San Diego,
California). In separate experiments, rC3dg tetramers were prepared
by incubating 2 g of in vivo biotinylated recombinant human C3dgImmunoprecipitation and SDS-PAGE Analysis
Splenic cell suspensions were depleted of RBC with Gey’s solution (Henson et al., 2001) with 0.4 g PE-streptavidin in a total volume
of 100 l for 30 min at room temperature. 100 l of PE-labeled C3dgand surface biotinylated with EZ-Link Sulfo-NHS-LC-Biotin (Pierce,
Rockford, Illinois). Cells were lysed with RIPA buffer supplemented tetramers in combination with FITC-B220 were incubated with 1 
106 cells for 30 min at 4C. Cells were analyzed on a FACSCaliburwith Complete protease inhibitor cocktail tablets (Boehringer Mann-
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(Becton Dickinson, San Jose, California) and mean amount of fluo- J.H. (1997). Crystal structure of ICAM-2 reveals a distinctive integrin
recognition surface. Nature 387, 312–315.rescence bound was determined.
Chen, Z., Koralov, S.B., and Kelsoe, G. (2000). Complement C4
Intracellular Calcium Measurements inhibits systemic autoimmunity through a mechanism independent
Splenic cell suspensions were depleted of RBC with Gey’s solution. of complement receptors CR1 and CR2. J. Exp. Med. 192, 1339–
Cells were loaded with Indo-1AM (Molecular Probes, Eugene, Ore- 1351.
gon) and B cells labeled with FITC-B220. Sufficiency of Indo-1 load-
Cornall, R.J., Cyster, J.G., Hibbs, M.L., Dunn, A.R., Otipoby, K.L.,ing was assessed by stimulation with 10 g of F(ab)	2 polyclonal
Clark, E.A., and Goodnow, C.C. (1998). Polygenic autoimmune traits:goat anti-mouse sIg (Southern Biotechnology Associates). Tetra-
Lyn, CD22, and SHP-1 are limiting elements of a biochemical path-mers prepared by incubating various amounts of b-rC3dg and/or
way regulating BCR signaling and selection. Immunity 8, 497–508.biotinylated rat anti-mouse IgM (b-7-6, provided by Dr. John Cam-
Croix, D.A., Ahearn, J.M., Rosengard, A.M., Han, S., Kelsoe, G., Ma,bier) with 0.2 g streptavidin (Biosource, Camarillo, California) were
M., and Carroll, M.C. (1996). Antibody response to a T-dependentadded to 2 106 cells and calcium flux of B220 cells was measured
antigen requires B cell expression of complement receptors. J. Exp.on a BD LSR (Becton Dickinson, San Jose, California). Results were
Med. 183, 1857–1864.analyzed using FlowJo software (Tree Star, Inc., San Carlos, Cali-
fornia). Dempsey, P.W., Allison, M.E.D., Akkaraju, S., Goodnow, C.C., and
Fearon, D.T. (1996). C3d of complement as a molecular adjuvant:
Immunization and Analyses of Humoral Immune Responses bridging innate and acquired immunity. Science 271, 348–350.
Five 6-week-old female B6.Sle1c and B6 mice were immunized intra-
Eastcott, J.W., Schwartz, R.S., and Datta, S.K. (1983). Genetic analy-
peritoneally with 10 g DNP-KLH in alum (1:1) on days 0 and 21,
sis of the inheritance of B cell hyperactivity in relation to the develop-
then sacrificed on day 28, at which time serum titers to DNP were
ment of autoantibodies and glomerulonephritis in NZB X SWR
determined by ELISA. ELISAs were performed by coating microtiter
crosses. J. Immunol. 131, 2232–2239.
wells with DNP-BSA, followed by sequential incubations with sera,
Fingeroth, J.D. (1990). Comparative structure and evolution of mu-HRP-conjugated anti-isotype antibodies, and substrate, as pre-
rine CR2: the homolog of the human C3d/EBV receptor (CD21). J.viously described (Mohan et al., 1997). The mean OD at 405 nm for
Immunol. 144, 3458–3467.each mouse was calculated from duplicate wells.
Fingeroth, J.D., Heath, M.E., and Ambrosino, D.M. (1989). Prolifera-
Molecular Modeling tion of resting B cells is modulated by CR2 and CR1. Immunol. Lett.
The human CR2 dimer from the CR2-C3d complex structure (Sza- 21, 291–302.
konyi et al., 2001) was used for modeling mouse CR2 using the Harley, J.B., Moser, K.L., Gaffney, P.M., and Behrens, T.W. (1998).
program “O” (Jones et al., 1991) on a Silicon Graphics workstation. The genetics of human systemic lupus erythematosus. Current Opin.
Oligosaccharide sugar residues used in the modeling were down- Immunol. 10, 690–696.
loaded from the PDB database [1ZXQ, (Casasnovas et al., 1997)].
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